Gene Therapy Restores Hearing in Patients with Rare Genetic Deafness

An experimental gene therapy has shown lasting success in restoring hearing for people born with a rare form of inherited deafness, according to results from a large international clinical trial published in April 2026. The treatment, which targets mutations in the OTOF gene, improved hearing in 90% of participants, with benefits lasting up to 2.5 years.

How the Therapy Works

The therapy addresses autosomal recessive deafness 9 (DFNB9), a condition caused by mutations in the OTOF gene. This gene provides instructions for making otoferlin, a protein essential for transmitting sound signals from the inner ear to the brain. When otoferlin is missing or defective due to genetic mutations, sound cannot be processed properly, resulting in profound deafness from birth.

Researchers used a harmless virus called adeno-associated virus type 1 (AAV1) to deliver a functional copy of the OTOF gene into the inner ear. This one-time treatment aims to restore the body’s ability to produce otoferlin, thereby enabling hearing function.

Trial Results Show Significant Improvement

The multicenter trial included 42 participants ranging in age from 0.8 to 32.3 years. After treatment, 90% of recipients experienced improved hearing. Over half of the patients achieved hearing levels within the normal range by the study’s endpoint at 2.5 years, allowing them to hear soft sounds such as a whisper.

Children under 18 showed the strongest responses to the therapy, with greater gains in both hearing sensitivity and speech recognition. Adults also benefited, though the improvements were more modest. Importantly, the treatment was found to be safe and well-tolerated across all age groups.

Broader Implications for Genetic Hearing Loss

While OTOF mutations account for only 2% to 8% of congenital hearing loss cases, researchers believe the success of this approach could pave the way for treatments targeting other genes involved in deafness. Over 200 genes are known to cause genetic hearing loss when mutated.

Scientists are already exploring ways to adapt the same gene therapy platform to address mutations in the GJB2 gene, which is the most common cause of inherited hearing loss worldwide. Early intervention remains critical, as treating young children during key periods of language development offers the best chance for normal speech acquisition.

Future Outlook

The positive results from this trial have increased momentum toward regulatory approval. A similar gene therapy developed by Regeneron Pharmaceuticals is under review by the U.S. Food and Drug Administration and could become the first approved treatment for genetic deafness.

Experts suggest that these advances may encourage expanded newborn screening for genetic forms of hearing loss, enabling earlier diagnosis and treatment. As research continues, gene therapy holds promise as a transformative option for individuals affected by inherited deafness.

Key Takeaways

• A gene therapy targeting the OTOF gene restored hearing in 90% of participants in a clinical trial of 42 people with inherited deafness.
• Improvements lasted up to 2.5 years, with over half of patients achieving normal hearing levels.
• Children under 18 showed the strongest gains in hearing and speech recognition.
• The treatment was safe and well-tolerated, with no serious safety concerns reported.
• Success with OTOF-related deafness may lead to therapies for other genetic forms of hearing loss, including those caused by GJB2 mutations.

Frequently Asked Questions

What is DFNB9?

DFNB9, or autosomal recessive deafness 9, is a genetic condition caused by mutations in the OTOF gene. It results in profound hearing loss at birth due to the absence of functional otoferlin, a protein needed for sound transmission in the inner ear.

Is this therapy a cure?

While not yet classified as a cure, the therapy provides long-lasting improvement in hearing function, with benefits demonstrated for at least 2.5 years after a single treatment. Ongoing follow-up will determine whether effects persist longer.

Who is eligible for this treatment?

Currently, the therapy is intended for individuals with confirmed OTOF gene mutations causing DFNB9. Eligibility in clinical trials has included infants, children, and young adults, with younger patients showing better outcomes.

When will this therapy be widely available?

Regulatory approval is pending, with potential authorization by the U.S. FDA in the near future if ongoing reviews remain positive. Widespread availability will depend on approval timelines and manufacturing scale-up.

Can this approach treat other types of genetic deafness?

Yes. Researchers are working to adapt the gene therapy platform to target other deafness-related genes, such as GJB2. The success with OTOF provides a proof of concept for broader application.